Skip to main content

Advertisement

SpringerLink
Log in

Pancreatic Neuroendocrine Tumors: an Update

  • Original Article
  • Published:
Indian Journal of Surgery Aims and scope Submit manuscript

Abstract

Pancreatic neuroendocrine tumors (pNETs) are rare and comprise only 1–2 % of all pancreatic neoplastic disease. Although the majority of these tumors are sporadic (90 %), pNETs can arise in the setting of several different hereditary genetic syndromes, most commonly multiple endocrine neoplasia type 1 (MEN1). The presentation of pNETs varies widely, with over 60 % having malignant distant disease at the time of initial diagnosis involving the liver or other distant sites. Functioning pNETs represent approximately 10 % of all pNETs, secrete a variety of peptide hormones, and are responsible for several clinical syndromes caused by profound hormonal derangement. Surgery remains the cornerstone of therapy and the only curative approach. It should be pursued for localized disease and for metastatic lesions amenable to resection. Multimodality therapies, including liver-directed therapies and medical therapy, are gaining increasing favor in the treatment of advanced pNETs. Their utility is multifold and spans from ameliorating symptoms of hormonal excess (functional pNETs) to controlling the local and systemic disease burden (non-functional pNETs). The recent introduction of target molecular therapy has promising results especially for the treatment of progressive well-differentiated G1/G2 tumor. In this review, we summarize the current knowledge and give an update on recent advancements made in the therapeutic strategies for pNETs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fraenkel M, Kim MK, Faggiano A, Valk GD (2012) Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 26(6):691–703

    Article  PubMed  CAS  Google Scholar 

  2. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am 40(1):1–18

    Article  Google Scholar 

  3. Vortmeyer AO, Huang S, Lubensky I, Zhuang Z (2004) Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab 89(4):1934–1938

    Article  PubMed  CAS  Google Scholar 

  4. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS et al (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021):1199–1203

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Metz DC, Jensen RT (2008) Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135(5):1469–1492

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. de Wilde RF, Edil BH, Hruban RH, Maitra A (2012) Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol 9:199–208

    Article  PubMed  PubMed Central  Google Scholar 

  7. Garbrecht N, Anlauf M, Schmitt A, Henopp T, Sipos B et al (2008) Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 15(1):229–241

    Article  PubMed  Google Scholar 

  8. Grimelius L, Hultquist GT, Stenkvist B (1975) Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material. Virchows Arch A Pathol Anat Histol 365:275–288

    Article  PubMed  CAS  Google Scholar 

  9. Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM (2008) Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer 15:409–427

    Article  PubMed  PubMed Central  Google Scholar 

  10. Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ (2008) Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg : Off J Soc Surg Aliment Tract 12:382–393

    Article  Google Scholar 

  11. Franko J, Feng W, Yip L, Genovese E, Moser AJ (2010) Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg : Off J Soc Surg Aliment Tract 14:541–548

    Article  Google Scholar 

  12. Thakker RV (2014) Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol 386:2–15

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Plöckinger U, Wiedenmann B (2004) Diagnosis of non-functioning neuro-endocrine gastro-enteropancreatic tumours. Neuroendocrinology 80(Suppl 1):35–38

    Article  PubMed  Google Scholar 

  14. Mehrabi A, Fischer L, Hafezi M, Dirlewanger A, Grenacher L et al (2014) A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas 43(5):675–686

    Article  PubMed  Google Scholar 

  15. Grant CS (2005) Insulinoma. Best Pract Res Clin Gastroenterol 19(5):783–798

    Article  PubMed  CAS  Google Scholar 

  16. de Metz J, Romijn JA, Gouma DJ, ten Berge IJ, Busch OR, Endert E, Sauerwein HP. (2002) Interferon-gamma administration does not affect human thyroid hormone metabolism in the post-surgical euthyroid sick syndrome. 25, 315–320

  17. Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT (2006) Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 85:295–330

    Article  CAS  Google Scholar 

  18. Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT (2006) Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 85(6):331–364

    Article  CAS  Google Scholar 

  19. de Metz J, Romijn JA, Gouma DJ, ten Berge IJ, Busch OR, Endert E, Sauerwein HP (2002) Interferon-gamma administration does not affect human thyroid hormone metabolism in the post-surgical euthyroid sick syndrome. J Endocrinol Investig 25(4):315–320

    Article  Google Scholar 

  20. Kanakis G, Kaltsas G (2012) Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol 26(6):791–802

    Article  PubMed  CAS  Google Scholar 

  21. Singh S, Law C (2012) Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 6(3):313–334

    Article  PubMed  CAS  Google Scholar 

  22. Vinik AI, Silva MP, Woltering EA, Go VL, Warner R, Caplin M (2009) Biochemical testing for neuroendocrine tumors. Pancreas 38(8):876–889

    Article  PubMed  Google Scholar 

  23. Oberg K (2011) Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 18(Suppl 1):S17–S25

    Article  PubMed  CAS  Google Scholar 

  24. Paik WH, Ryu JK, Song BJ, Kim J, Park JK, Kim YT, Yoon YB (2013) Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm. J Korean Med Sci 28(5):750–754

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Sundin A (2012) Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 26(6):803–818

    Article  PubMed  Google Scholar 

  26. Singhi AD, Chu LC, Tatsas AD, Shi C, Ellison TA et al (2012) Cystic pancreatic neuroendocrine tumors: a clinicopathologic study. Am J Surg Pathol 36(11):1666–1673

    Article  PubMed  Google Scholar 

  27. Sundin A, Vullierme MP, Kaltsas G, Plöckinger U, Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 90(2):167–183

    Article  PubMed  CAS  Google Scholar 

  28. Oberg K (2012) Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors. Clinics (Sao Paulo) 67(Suppl 1):109–112

    Article  Google Scholar 

  29. Joseph S, Wang YZ, Boudreaux JP, Anthony LB, Campeau R et al (2011) Neuroendocrine tumors: current recommendations for diagnosis and surgical management. Endocrinol Metab Clin N Am 40(1):205–231. doi:10.1016/j.ecl.2010.08.004

    Article  Google Scholar 

  30. de Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO et al (2005) Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Investig 28(11 Suppl International):132–136

    Google Scholar 

  31. Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard AS et al (2009) Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 50(6):858–864

    Article  PubMed  CAS  Google Scholar 

  32. Panagiotidis E, Bomanji J (2014) Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors. PET Clin 9(1):43–55

    Article  PubMed  Google Scholar 

  33. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J (2010) The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 51(6):875–882

    Article  PubMed  CAS  Google Scholar 

  34. Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plöckinger U (2010) Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 12(6):361–379

    Article  Google Scholar 

  35. Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ (2012) High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol 56(1):40–47

    Article  PubMed  Google Scholar 

  36. Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P et al (2010) 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 51(5):669–673

    Article  PubMed  Google Scholar 

  37. Rufini V, Baum RP, Castaldi P, Treglia G, De Gaetano AM et al (2012) Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging 37(6):1004–1020

    Article  PubMed  Google Scholar 

  38. Kim MK (2012) Endoscopic ultrasound in gastroenteropancreatic neuroendocrine tumors. Gut Liver 6(4):405–410

    Article  PubMed  PubMed Central  Google Scholar 

  39. Atiq M, Bhutani MS, Bektas M, Lee JE, Gong Y et al (2012) EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience. Dig Dis Sci 57(3):791–800

    Article  PubMed  CAS  Google Scholar 

  40. Lennon AM, Newman N, Makary MA, Edil BH, Shin EJ et al (2010) EUS-guided tattooing before laparoscopic distal pancreatic resection (with video). Gastrointest Endosc 72(5):1089–1094

    Article  PubMed  Google Scholar 

  41. Klimstra DS, Armold R, Capella C, et al (2010) Neuroendocrine neoplasms of the pancreas. In: Bosman F, Carneiro F, Hruban RH, et al (eds) WHO classification of tumours of the digestive system. IARC Press, Lyon, pp 322–326

  42. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, et al. (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. in 449(4): 395–401

  43. McKenna LR, Edil BH (2014) Update on pancreatic neuroendocrine tumors. Gland Surg 3(4):258–275

    PubMed  PubMed Central  Google Scholar 

  44. Ellison TA, Wolfgang CL, Shi C, Cameron JL, Murakami P et al (2014) A single institution’s 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg 259(2):204–212

    Article  PubMed  PubMed Central  Google Scholar 

  45. Strosberg JR, Cheema A, Weber JM, Ghayouri M, Han G et al (2012) Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg 256(2):321–325

    Article  PubMed  Google Scholar 

  46. Liu TC, Hamilton N, Hawkins W, Gao F, Cao D (2013) Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 37(6):853–859

    Article  PubMed  PubMed Central  Google Scholar 

  47. Cauley CE, Pitt HA, Ziegler KM, Nakeeb A, Schmidt CM et al (2012) Pancreatic enucleation: improved outcomes compared to resection. J Gastrointest Surg 16(7):1347–1353

    Article  PubMed  CAS  Google Scholar 

  48. Pitt SC, Pitt HA, Baker MS, Christians K, Touzios JG et al (2009) Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? J Gastrointest Surg 13(9):1692–1698

    Article  PubMed  PubMed Central  Google Scholar 

  49. Casadei R, Ricci C, Rega D, D’Ambra M, Pezzilli R et al (2010) Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? A single-center experience. Pancreas 39(6):825–828

    Article  PubMed  Google Scholar 

  50. Hackert T, Hinz U, Fritz S, Strobel O, Schneider L et al (2011) Enucleation in pancreatic surgery: indications, technique, and outcome compared to standard pancreatic resections. Langenbecks Arch Surg 396(8):1197–1203

    Article  PubMed  Google Scholar 

  51. Falconi M, Zerbi A, Crippa S, Balzano G, Boninsegna L et al (2010) Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. Ann Surg Oncol 17(6):1621–1627

    Article  PubMed  Google Scholar 

  52. Lavu H, Knuth JL, Baker MS, Shen C, Zyromski NJ et al (2008) Middle segment pancreatectomy can be safely incorporated into a pancreatic surgeon’s clinical practice. HPB 10(6):491–497

    Article  PubMed  PubMed Central  Google Scholar 

  53. Du ZY, Chen S, Han BS, Shen BY, Liu YB, Peng CH (2013) Middle segmental pancreatectomy: a safe and organ-preserving option for benign and low-grade malignant lesions. World J Gastroenterol 19(9):1458–1465

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  54. Shikano T, Nakao A, Kodera Y, Yamada S, Fujii T et al (2010) Middle pancreatectomy: safety and long-term results. Surgery 147(1):21–29

    Article  PubMed  Google Scholar 

  55. Crippa S, Boninsegna L, Partelli S, Falconi M (2010) Parenchyma-sparing resections for pancreatic neoplasms. J Hepatobiliary Pancreatol Sci 17(6):782–787

    Article  Google Scholar 

  56. Kooby DA, Chu CK (2010) Laparoscopic management of pancreatic malignancies. Surg Clin N Am 90(2):427–446

    Article  PubMed  Google Scholar 

  57. Kuroki T, Eguchi S (2014) Laparoscopic parenchyma-sparing pancreatectomy. J Hepatobiliary Pancreatol Sci 21(5):323–327

    Article  Google Scholar 

  58. Cheng K, Shen B, Peng C, Deng X, Hu S (2013) Initial experiences in robot-assisted middle pancreatectomy. HPB (Oxford) 15(4):315–332

    Article  Google Scholar 

  59. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ et al (2010) NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39(6):735–752

    Article  PubMed  PubMed Central  Google Scholar 

  60. Bettini R, Mantovani W, Boninsegna L, Crippa S, Capelli P et al (2009) Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis 41(1):49–55

    Article  PubMed  CAS  Google Scholar 

  61. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197(1):29–37

    Article  PubMed  Google Scholar 

  62. Ito T, Igarashi H, Jensen RT (2012) Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol 47(9):941–960

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  63. Jaeck D, Oussoultzoglou E, Bachellier P, Lemarque P, Weber JC et al (2001) Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg 25(6):689–692

    Article  PubMed  CAS  Google Scholar 

  64. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W et al (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190(4):432–445

    Article  PubMed  CAS  Google Scholar 

  65. Cusati D, Zhang L, Harmsen WS, Hu A, Farnell MB et al (2012) Metastatic nonfunctioning pancreatic neuroendocrine carcinoma to liver: surgical treatment and outcomes. J Am Coll Surg 215(1):117–124, discussion 124–5

    Article  PubMed  Google Scholar 

  66. Norton JA (2005) Endocrine tumours of the gastrointestinal tract. Surgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol 19(4):577–583

    Article  PubMed  Google Scholar 

  67. Que FG, Sarmiento JM, Nagorney DM (2006) Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Adv Exp Med Biol 574:43–56

    Article  PubMed  Google Scholar 

  68. Gaujoux S, Gonen M, Tang L, Klimstra D, Brennan MF et al (2012) Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann Surg Oncol 19(13):4270–4277

    Article  PubMed  Google Scholar 

  69. De Jong MC, Farnell MB, Sclabas G, Cunningham SC, Cameron JL et al (2010) Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg 252(1):142–148

    Article  PubMed  Google Scholar 

  70. Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B et al (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87(1):47–62

    Article  PubMed  Google Scholar 

  71. Siperstein AE, Berber E (2001) Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 25(6):693–696

    Article  PubMed  CAS  Google Scholar 

  72. Mazzaglia PJ, Berber E, Milas M, Siperstein AE (2007) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142(1):10–19

    Article  PubMed  Google Scholar 

  73. Gillams A, Cassoni A, Conway G, Lees W (2005) Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 30(4):435–441

    Article  PubMed  CAS  Google Scholar 

  74. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A (2010) 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 16(3):978–985

    Article  PubMed  CAS  Google Scholar 

  75. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D et al (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48(4):508–518

    Article  PubMed  CAS  Google Scholar 

  76. Milan SA, Yeo CJ (2012) Neuroendocrine tumors of the pancreas. Curr Opin Oncol 24(1):46–55

    Article  PubMed  Google Scholar 

  77. Alistar A, Sung M, Kim M, Holcombe RF (2012) Clinical pathways for pancreatic neuroendocrine tumors. J Gastrointest Cancer 43(4):532–540

    Article  PubMed  Google Scholar 

  78. Reidy-Lagunes D, Thornton R (2012) Pancreatic neuroendocrine and carcinoid tumors: what’s new, what’s old, and what’s different? Curr Oncol Rep 14(3):249–256

    Article  PubMed  CAS  Google Scholar 

  79. Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C et al (2008) Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31(3):271–279

    Article  PubMed  Google Scholar 

  80. King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, Morris DL (2008) Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113(5):921–929

    Article  PubMed  Google Scholar 

  81. Frilling A, Malago M, Weber F, Paul A, Nadalin S et al (2006) Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver Transpl 12(7):1089–1096

    Article  PubMed  Google Scholar 

  82. Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O et al (2007) Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl 13(3):327–333

    Article  PubMed  Google Scholar 

  83. Rosenau J, Bahr MJ, von Wasielewski R, Mengel M, Schmidt HH et al (2002) Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 73(3):386–394

    Article  PubMed  CAS  Google Scholar 

  84. Lehnert T (1998) Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 66(10):1307–1312

    Article  PubMed  CAS  Google Scholar 

  85. Mazzaferro V, Pulvirenti A, Coppa J (2007) Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol 47(4):460–466

    Article  PubMed  Google Scholar 

  86. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB et al (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22(23):4762–4771

    Article  PubMed  CAS  Google Scholar 

  87. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117(2):268–275

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  88. Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S et al (2013) Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol 71(3):663–670

    Article  PubMed  CAS  Google Scholar 

  89. Saif MW, Kaley K, Brennan M, Garcon MC, Rodriguez G, Rodriguez T (2013) A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. JOP 14(5):498–501

    PubMed  Google Scholar 

  90. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ et al (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61(1):6–32

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  91. Panzuto F, Di Fonzo M, Iannicelli E, Sciuto R, Maini CL et al (2006) Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 17(3):461–466

    Article  PubMed  CAS  Google Scholar 

  92. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28):4656–4663

    Article  PubMed  CAS  Google Scholar 

  93. Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K et al (2014) Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 41(5):925–933

    Article  PubMed  CAS  Google Scholar 

  94. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26(13):2124–2130

    Article  PubMed  CAS  Google Scholar 

  95. Nicolas G, Giovacchini G, Müller-Brand J, Forrer F (2011) Targeted Radiotherapy with Radiolabeled Somatostatin Analogs. Endocrinol Metab Clin N Am 40(1):187–204

    Article  CAS  Google Scholar 

  96. Kwekkeboom DJ, de Herder WW, Krenning EP (2011) Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am 40(1):173–185

    Article  CAS  Google Scholar 

  97. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  98. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of Interest

No conflicts of interest are declared.

Author information

Authors and Affiliations

  1. Division of GI, Tumor and Endocrine Surgery, Department of Surgery, University of Colorado at Denver, Aurora, CO, USA

    Alessandro Paniccia, Barish H. Edil & Richard D. Schulick

  2. Department of Surgery, University of Colorado Anschutz Medical Campus, 12631 E. 17th Avenue, C-305, Aurora, CO, 80045, USA

    Richard D. Schulick

Authors
  1. Alessandro Paniccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barish H. Edil
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard D. Schulick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard D. Schulick.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Paniccia, A., Edil, B.H. & Schulick, R.D. Pancreatic Neuroendocrine Tumors: an Update. Indian J Surg 77, 395–402 (2015). https://doi.org/10.1007/s12262-015-1360-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12262-015-1360-2

Keywords

Search

Navigation